Shield Therapeutics translating positive signals into sales (VIDEO)

Shield Therapeutics plc (LON:STX) is the topic of conversation when Hardman & Co Analyst Dr Martin Hall joins DirectorsTalk Interviews.

Despite launching a drug into the US market, Shield has performed really badly over the past 12 months, Martin explains what happened, shares his thoughts on the considerable progress made, implications for the full year, why the share price is falling, investment capital and the investment opportunity.

Shield Therapeutics is a specialty pharmaceutical company focused on the development and commercialisation of late‑stage, hospital‑focused pharmaceuticals.

You might also enjoy reading  Surface Transforms its all in the detail (VIDEO)
Find more news, interviews, share price & company profile here for:
Hardman & Co

Share this interview

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on whatsapp
WhatsApp
Shield Therapeutics translating positive signals into sales (VIDEO)

Other Interviews

More News

Ask your questions

Do you have questions you’d like to ask this company, get in touch and we’ll ask them for you.   

I have questions